A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj. in Primary Immune Thrombocytopenia (ITP)

Inclusion Criteria: * Diagnosis of ITP * Mean screening platelet count of \<30×10\^9/L from 3 qualifying platelet counts performed within 14 days before the start of treatment, with no individual platelet count above 35×10\^9/L. * No other factors inducing ITP * Stable doses of ITP active treatment must not have modified the dose in the preceding 1 month and must maintain their prestudy dose during the study. Exclusion Criteria: * Known for hypersensitivity reactions to blood products, intravenous immunoglobulin (IVIg) or immunoglobulin G * Immunoglobulin A (IgA) deficiency * Therapy with live attenuated virus vaccines 3 months before the first administration of LIV-GAMMA SN Inj. * Administration of other investigational product 1 month before the first administration of LIV-GAMMA SN Inj. * Administration of Rituximab 3 months before the first administration of LIV-GAMMA SN Inj. * Treatment with anti-coagulants, which may affect the function of platelet * Positive HIV, HBV, HCV * 3-fold increase of ALT or AST compared to normal upper limit * eCFR \< 30mL/min/1.73m\^2 * History of deep vein thrombosis (DVT) or IVIg-induced thrombotic compliances * Hemoglobin \> 10g/dL